Review in Biofabrication, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Hyeonji KimDepartment of Ophthalmology, School of Medicine, Byers Eye Institute at Stanford University, Palo Alto, CA 94304, United States of America.ORCID 0009-0009-6918-6564
Nae-Won KangDepartment of Ophthalmology, School of Medicine, Byers Eye Institute at Stanford University, Palo Alto, CA 94304, United States of America.
Wen HongDepartment of Ophthalmology, School of Medicine, Byers Eye Institute at Stanford University, Palo Alto, CA 94304, United States of America.
Sajjad AbdollahramezaniDepartment of Ophthalmology, School of Medicine, Byers Eye Institute at Stanford University, Palo Alto, CA 94304, United States of America.
Gia-Han NgoDepartment of Ophthalmology, School of Medicine, Byers Eye Institute at Stanford University, Palo Alto, CA 94304, United States of America.ORCID 0009-0007-8981-3153
Daanyal RajaDepartment of Ophthalmology, School of Medicine, Byers Eye Institute at Stanford University, Palo Alto, CA 94304, United States of America.ORCID 0000-0002-1419-5297
Olivia PetersDepartment of Ophthalmology, School of Medicine, Byers Eye Institute at Stanford University, Palo Alto, CA 94304, United States of America.ORCID 0009-0007-3188-8187
Vinit B MahajanDepartment of Ophthalmology, School of Medicine, Byers Eye Institute at Stanford University, Palo Alto, CA 94304, United States of America.ORCID 0000-0003-1886-1741
David MyungDepartment of Ophthalmology, School of Medicine, Byers Eye Institute at Stanford University, Palo Alto, CA 94304, United States of America.
Charles DeBoerDepartment of Ophthalmology, School of Medicine, Byers Eye Institute at Stanford University, Palo Alto, CA 94304, United States of America.
Funding
Stanford Vision Research CoreP30EY026877 · NEI · STANFORD UNIVERSITY · PI Jeffrey L Goldberg · 2017 to 2026
$8.0M
Lens Capsule Based Extended Drug Delivery DeviceK08EY036955 · NEI · STANFORD UNIVERSITY · PI Charles Meno Theodore DeBoer · 2025 to 2026
$516k
NEI NIH HHS K08 EY036955NEI NIH HHS P30 EY026877
6 · The paper itself
Abstract
Despite the rapid pace of biomedical engineering research, translating developed products into clinical practice remains challenging due to regulations, manufacturing, and long-term
Indexed as
Eye DiseasesProstheses and ImplantsAnimalsBiocompatible MaterialsDrug Delivery SystemsEyeHumansBiocompatible Materialsclinical trialdrug deliveryeye implantocular therapeutic systemophthalmic devicetranslational medicine
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Implantable ocular therapeutic systems: an insight into their clinical potential in the long-term treatment of ocular diseases. · full record | OpenQuestion